ClinicalTrials.Veeva

Menu

Multi-modal Adverse Events Prediction for Premature Coronary Heart Disease Trial: MAP-CHD Trial

N

National Center for Cardiovascular Diseases

Status

Enrolling

Conditions

Premature Coronary Heart Disease

Study type

Observational

Funder types

Other

Identifiers

NCT07004452
2023ZD0504003

Details and patient eligibility

About

The goal of this observational cohort study is to establish a risk prediction model for adverse events in Chinese individuals under 45 years old with premature coronary artery disease. The main questions it aims to answer are:

  • What are the major risk factors for poor prognosis in Chinese patients with premature coronary artery disease?
  • What is the difference in the prognosis of patients with premature coronary heart disease with different phenotypes? Participants taking no mandatory intervention will be followed up for 2 year, with blood tests at 1 year and outpatient or telephone interviews at other timepoints.

Enrollment

5,000 estimated patients

Sex

All

Ages

18 to 45 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age 18-45 years;
  • Clinically confirmed CAD with ≥50% luminal stenosis in at least one major coronary artery or significant branch, verified by coronary angiography;
  • For acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI) patients: clinical stability meeting discharge criteria post-treatment;
  • Voluntary participation with signed informed consent.

Exclusion criteria

  • Heart transplant recipients;
  • Severe systemic comorbidities with life expectancy <1 year;
  • Previous enrollment in other drug/device clinical trials without completing the primary endpoint observation period;
  • Inability to comply with follow-up (e.g., dementia, severe psychiatric disorders).

Trial contacts and locations

1

Loading...

Central trial contact

Jingjing Xu

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems